AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean METAVIR fibrosis score
Number of subjects: 395
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 395
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV viral load
Number of subjects: 395
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 395
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and HCV viral load
Number of subjects: 395
Study 16470116 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean METAVIR fibrosis score, BMI, and ferritin
Number of subjects: 395
Study 15494907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin (33 mg/kg followed by 16 mg/kg every 6 h for 4 days and 8 mg/kg every 8 h for 3 days)
Number of subjects: 36
Study 15494907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered for 7 days or until negative Sin Nombre virus antibody test)
Number of subjects: 36
Study 11069502 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA sunbed treatment
Number of subjects: 38
Study 11069502 — intervention group
Group type: COMPARATOR
Intervention: Placebo visible light exposure
Number of subjects: 38
Study 9132126 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 0.1%
Number of subjects: 99
Study 9132126 — intervention group
Group type: COMPARATOR
Intervention: flurbiprofen 0.03%
Number of subjects: 99
Study 9132126 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 1.0%
Number of subjects: 99
Study 8443028 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol-Oros 14/190 once daily
Number of subjects: 12
Study 8443028 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg twice daily
Number of subjects: 12
Study 8443028 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam 10 mg once daily
Number of subjects: 12
Study 8443028 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 12
Study 8443028 — intervention group
Group type: COMPARATOR
Intervention: metoprolol-Oros
Number of subjects: 12
Study 8443028 — intervention group
Group type: COMPARATOR
Intervention: metoprolol-Oros and propranolol
Number of subjects: 12
Study 8443028 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam
Number of subjects: 12
Study 3533085 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 200 mg/ml
Number of subjects: 87
Study 3533085 — intervention group
Group type: COMPARATOR
Intervention: indoprofen 200 mg
Number of subjects: 87
Study 30376097 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 70%
Number of subjects: 1652
Study 30376097 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 30%
Number of subjects: 1652
Study 30376097 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 10%
Number of subjects: 1652
Study 30376097 — intervention group
Group type: COMPARATOR
Intervention: Household contacts of vaccinated subjects
Number of subjects: 1652
Study 30376097 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated households
Number of subjects: 1652
Study 27187447 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐Mix (1000 mg quercetin, 400 mg isoquercetin, 120 mg EGCG, 400 mg n3‐PUFAs, 1000 mg vitamin C, 40 mg niacinamide, 800 µg folic acid)
Number of subjects: 48
Study 27187447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27187447 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐Mix
Number of subjects: 48
Study 24421305 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole information aid (IA) - group A (5 SIMS-Trial centres)
Number of subjects: 159
Study 24421305 — intervention group
Group type: COMPARATOR
Intervention: Take-home booklet/website component - group B (16 centres)
Number of subjects: 159
Study 24421305 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole information aid (IA) - group A
Number of subjects: 159
Study 24421305 — intervention group
Group type: COMPARATOR
Intervention: Take-home booklet/website component - group B
Number of subjects: 159
Study 22554876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative physical therapy protocol (passive elevation and rotation starting at postoperative day 2)
Number of subjects: 68
Study 22554876 — intervention group
Group type: COMPARATOR
Intervention: Delayed postoperative physical therapy protocol (passive elevation and rotation starting at 6 weeks)
Number of subjects: 68
Study 19468821 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma amino acids
Number of subjects: 80
Study 19468821 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of amino acids
Number of subjects: 80
Study 19468821 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids in blood and urine
Number of subjects: 80
Study 19468821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age‐matched reference values
Number of subjects: 80
Study 16549375 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, followed by 75 mg daily for 30 days)
Number of subjects: 67
Study 15298642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid immunochromatographic stool test before treatment
Number of subjects: 303
Study 15298642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid immunochromatographic stool test after treatment
Number of subjects: 303
Study 11380832 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg q.d. added to lisinopril 40 mg q.d. and other antihypertensive therapy
Number of subjects: 16
Study 11380832 — intervention group
Group type: COMPARATOR
Intervention: lisinopril 40 mg q.d. and other antihypertensive therapy
Number of subjects: 16
Study 9401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6
Study 9401940 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 6
Study 8509590 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (5 sessions per week for 12 weeks at 60% of heart rate reserve)
Number of subjects: 30
Study 8509590 — intervention group
Group type: COMPARATOR
Intervention: Calisthenics program (5 sessions per week for 12 weeks at 60% of heart rate reserve)
Number of subjects: 30
Study 8509590 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional comparison of highly conditioned elderly women
Number of subjects: 30
Study 3433015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion (0.9 micrograms/kg/h, intravenously)
Number of subjects: 5
Study 3433015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 5
Study 3433015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.7 and 7.0 micrograms/kg, intramuscularly) before sham feeding
Number of subjects: 5
Study 3433015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.0 micrograms/kg, intramuscularly) before pentagastrin
Number of subjects: 5
Study 29732223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Number of subjects: 88
Study 29732223 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Number of subjects: 88
Study 29732223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Number of subjects: 88
Study 29732223 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Number of subjects: 88
Study 27757026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 50 mg/d for 5-8 years
Number of subjects: 7469
Study 24679247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Androgen Deprivation (IAD)
Number of subjects: 554
Study 24679247 — intervention group
Group type: COMPARATOR
Intervention: Continuous Androgen Deprivation (CAD)
Number of subjects: 554
Study 24679247 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Number of subjects: 554
Study 23369996 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (three meetings, each lasting 1.5 hours)
Number of subjects: 322
Study 23369996 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 322
Study 23369996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study 19684008 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS medication
Number of subjects: 21
Study 19684008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18368070 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL‐MB 91 (N=358)
Number of subjects: 713
Study 18368070 — intervention group
Group type: COMPARATOR
Intervention: ALL‐BFM 90m (N=355)
Number of subjects: 713
Study 18368070 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL‐MB 91 (N=197)
Number of subjects: 713
Study 18368070 — intervention group
Group type: COMPARATOR
Intervention: ALL‐BFM 90m (N=197)
Number of subjects: 713
Study 16143681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subject research design
Number of subjects: 0
Study 12772108 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 123
Study 12772108 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 123
Study 11103174 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (56%)
Number of subjects: 20
Study 11103174 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.8 MAC)
Number of subjects: 20
Study 9282505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) at a dose of 20 mg/kg/day up to a maximum of 850 mg/day for 4 weeks
Number of subjects: 180
Study 9282505 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole at a dose of 600 mg/day in 3 divided doses for 4 weeks
Number of subjects: 180
Study 9282505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG)
Number of subjects: 180
Study 9282505 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 180
Study 8280551 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 4 mg
Number of subjects: 123
Study 8280551 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 123
Study 3437450 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal skills training curriculum
Number of subjects: 0
Study 3437450 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 3437450 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent messages mailed to students' homes
Number of subjects: 0
Study 29954606 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive high-frequency oscillatory ventilation
Number of subjects: 0
Study 29954606 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (Control)
Number of subjects: 0
Study 26408266 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Number of subjects: 50
Study 26408266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen tonometry
Number of subjects: 50
Study 26408266 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 50
Study 24559581 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation and follow-up by a palliative care team
Number of subjects: 461
Study 24559581 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 461
Study 23876566 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion‐Mindfulness Therapy (C‐MT)
Number of subjects: 82
Study 23876566 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 82
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: epinastine
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: olopatadine
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: fluorometholone
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: naphazoline/antazoline
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: cromolyn sodium/chlorpheniramine maleate
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 240
Study 20383847 — intervention group
Group type: EXPERIMENTAL
Intervention: levocabastine
Number of subjects: 240
Study 18662492 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 1000
Study 18662492 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg QD
Number of subjects: 1000
Study 18662492 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg QD
Number of subjects: 1000
Study 18662492 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 1000
Study 18662492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 17405287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC)
Number of subjects: 129
Study 12666950 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (fosamax), one tablet every morning for six months
Number of subjects: 24
Study 12666950 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 24
Study 11421377 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (AP) 1,000 mg + 400 mg once daily for 3 days
Number of subjects: 48
Study 11421377 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine (HF) 1,500 mg in 3 doses
Number of subjects: 48
Study 8840413 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for 7 days
Number of subjects: 0
Study 8840413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8840413 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 0
Study 1643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Almagate (0.25 to 0.5 mL/kg every 2 hrs by nasogastric tube)
Number of subjects: 140
Study 1643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (1.5 mg/kg every 6 hrs iv)
Number of subjects: 140
Study 1643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (0.5 to 1 g every 6 hrs by nasogastric tube)
Number of subjects: 140
Study 1643886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study 6338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate
Number of subjects: 124
Study 6338251 — intervention group
Group type: COMPARATOR
Intervention: Cis-platinum
Number of subjects: 124
Study 6338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate plus cis-platinum
Number of subjects: 124
Study 6338251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (estramustine phosphate plus cis-platinum)
Number of subjects: 124
Study 6338251 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 124
Study 31381538 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz, 1200 pulses at 80% resting motor threshold)
Number of subjects: 21
Study 31381538 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study 28420122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0 g/day of NaCl)
Number of subjects: 44
Study 28420122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet supplemented with potassium (18.0 g/day of NaCl + 4.5 g/day of KCl)
Number of subjects: 44
Study 28420122 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (3.0 g/day of NaCl)
Number of subjects: 44
Study 26054688 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged capecitabine chemotherapy (1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX)
Number of subjects: 307
Study 26054688 — intervention group
Group type: COMPARATOR
Intervention: XELOX (oxaliplatin 130mg/m² on day 1 and oral capecitabine 1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles)
Number of subjects: 307
Study 23803900 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg dose of whole-virion inactivated H5N1 vaccine
Number of subjects: 0
Study 23803900 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg dose of whole-virion inactivated H5N1 vaccine
Number of subjects: 0
Study 21822058 — intervention group
Group type: COMPARATOR
Intervention: Normal isocaloric diet (balanced in fruits and vegetables)
Number of subjects: 88
Study 21822058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched in flavonoids and isothiocyanates (cruciferous vegetables)
Number of subjects: 88
Study 21822058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 supplemented with flavonoids (green tea and soy products)
Number of subjects: 88
Study 19317862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 40
Study 19317862 — intervention group
Group type: COMPARATOR
Intervention: Mechanomyography (MMG)
Number of subjects: 40
Study 19317862 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AMG and MMG
Number of subjects: 40
Study 16512048 — intervention group
Group type: EXPERIMENTAL
Intervention: Conveen Optima urinary sheath
Number of subjects: 10
Study 16512048 — intervention group
Group type: COMPARATOR
Intervention: Clear Advantage urinary sheath
Number of subjects: 10
Study 15684845 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care team recommendations
Number of subjects: 100
Study 11453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 10 or 15 J cm(‐2) on days 1 or 2 after injection.
Number of subjects: 187
Study 11453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 5-15 J cm(‐2).
Number of subjects: 187
Study 9236900 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative brachytherapy (BT) with a mean dose of 57 Gy (range: 50-60)
Number of subjects: 68
Study 9236900 — intervention group
Group type: COMPARATOR
Intervention: Post-operative external beam irradiation (EBI) with a mean dose of 50 Gy
Number of subjects: 68
Study 8325311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU streptokinase over 60 min
Number of subjects: 125
Study 8325311 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U anistreplase over 5 min
Number of subjects: 125
Study 8325311 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (streptokinase and anistreplase)
Number of subjects: 125
Study 2871787 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 88
Study 2871787 — intervention group
Group type: COMPARATOR
Intervention: Ipecac-induced Emesis (IE)
Number of subjects: 88
Study 31829725 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor exercise when Air Quality Health Index was ≥5
Number of subjects: 72
Study 31829725 — intervention group
Group type: COMPARATOR
Intervention: Outdoor exercise every day (Control)
Number of subjects: 72
Study 31605524 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (n = 20)
Number of subjects: 37
Study 31605524 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 37
Study 31605524 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 37
Study 31605524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 28333353 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir+lamivudine dual therapy
Number of subjects: 201
Study 28333353 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir-based triple therapy
Number of subjects: 201
Study 28333353 — intervention group
Group type: COMPARATOR
Intervention: Comparison between dual therapy and triple therapy
Number of subjects: 201
Study 26345959 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-CIK therapy combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Number of subjects: 63
Study 26345959 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Number of subjects: 63
Study 24635460 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical priming
Number of subjects: 1004
Study 24635460 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cervical priming
Number of subjects: 1004
Study 22011308 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 0
Study 22011308 — intervention group
Group type: COMPARATOR
Intervention: Start-up exercise programme
Number of subjects: 0
Study 20078006 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to research participation
Number of subjects: 0
Study 20078006 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential solutions to research challenges
Number of subjects: 0
Study 17035433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-relief CPAP (PRCPAP)
Number of subjects: 52
Study 17035433 — intervention group
Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 52
Study 15319596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-head coincidence gamma camera (DHC) with integrated X-ray transmission system
Number of subjects: 35
Study 15319596 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 35
Study 15319596 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 35
Study 15319596 — intervention group
Group type: EXPERIMENTAL
Intervention: DHC with integrated image fusion (FDHC)
Number of subjects: 35
Study 15319596 — intervention group
Group type: COMPARATOR
Intervention: DHC compared to CT
Number of subjects: 35
Study 12470180 — intervention group
Group type: EXPERIMENTAL
Intervention: DZP rectal gel
Number of subjects: 96
Study 12470180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96